Imagion Signs First US Site Agreement for HER2 Breast Cancer Trial
IBX: $0.006 +50.00% · MC: $4M
Imagion Biosystems has signed its first US clinical trial site agreement for its MagSense HER2+ breast cancer imaging agent, with patient recruitment anticipated to begin shortly after site activation. Site-startup activities are underway at seven selected sites, and the trial is registered on ClinicalTrials.gov; the company expects the study to take 18–24 months.

Comments